MAPLE GROVE, Minn. — Upsher-Smith Laboratories entered into an exclusive agreement with an emerging pharmaceutical company to market and distribute three generic products. These products will compete in markets with combined U.S. annual sales of nearly $200 million, according to IMS Health.
Under the terms of the agreement, the partner will develop, manufacture and supply the products exclusively for Upsher-Smith, which will market and distribute the products under its own label in the United States.
Financial terms related to the deal have not been disclosed. The name of the pharmaceutical company was not revealed in a news release.
"We are pleased to have entered into a partnership that will help Upsher-Smith build on its already strong presence in the U.S. generic marketplace," said Rusty Field, President, Upsher-Smith. "We look forward to creating more such partnerships with companies who share in our commitment to delivering quality, high-value generic products to patients."
Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals' lives.